Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · IEX Real-Time Price · USD
1.710
-0.150 (-8.06%)
At close: May 17, 2024, 4:00 PM
1.760
+0.050 (2.92%)
After-hours: May 17, 2024, 7:51 PM EDT
Atai Life Sciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Atai Life Sciences stock have an average target of 12, with a low estimate of 6.00 and a high estimate of 15. The average target predicts an increase of 601.75% from the current stock price of 1.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ATAI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 3 | 3 | 2 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 2 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 4 | 4 | 3 | 5 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +777.19% | May 17, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 4, 2024 |
Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $6 | Hold → Strong Buy | Upgrades | $6 | +250.88% | Apr 3, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +777.19% | Apr 3, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +1,069.59% | Mar 27, 2024 |
Financial Forecast
Revenue This Year
306.00K
from 314.00K
Decreased by -2.55%
Revenue Next Year
13.42M
from 306.00K
Increased by 4,283.99%
EPS This Year
-0.76
from -0.25
EPS Next Year
-0.72
from -0.76
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 1.6M | 67.5M | 193.0M | 710.4M | 1.5B |
Avg | 306,000 | 13.4M | 47.3M | 157.4M | 411.0M |
Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 401.6% | 21,950.0% | 1,338.6% | 1,403.5% | 836.9% |
Avg | -2.5% | 4,284.0% | 252.2% | 233.2% | 161.0% |
Low | - | - | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.62 | -0.55 | -0.50 | 2.99 | 7.37 |
Avg | -0.76 | -0.72 | -0.64 | 1.11 | 3.07 |
Low | -0.91 | -0.99 | -0.76 | -0.67 | -0.98 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 566.0% |
Avg | - | - | - | - | 177.4% |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.